NCT05106946View on ClinicalTrials.gov

Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 25, 2021

Primary Completion Date

October 25, 2023

Study Completion Date

October 25, 2024

Conditions
B-cell Malignancy
Interventions
BIOLOGICAL

ThisCART22 cells

0.2-60 x 10\^6 CAR T cells per kg body weight

Trial Locations (1)

Unknown

RECRUITING

The Affiliated Hospital of Xuzhou Medical University, Xuzhou

Sponsors
All Listed Sponsors
lead

Fundamenta Therapeutics, Ltd.

INDUSTRY

collaborator

The Affiliated Hospital of Xuzhou Medical University

OTHER

NCT05106946 - Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma | Biotech Hunter | Biotech Hunter